{"id":"cayston","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Wheezing"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Hemoptysis"}]},"_chembl":null,"_dailymed":{"setId":"67300ca3-8c53-4ce4-8e86-2c03be1f9b8a","title":"CAYSTON (AZTREONAM) KIT [GILEAD SCIENCES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aztreonam lysine is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. When inhaled as a powder, it achieves high local concentrations in the airways, effectively penetrating and disrupting biofilms formed by Pseudomonas aeruginosa in cystic fibrosis patients, thereby reducing bacterial burden and improving lung function.","oneSentence":"Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:09.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection"}]},"trialDetails":[{"nctId":"NCT03219164","phase":"PHASE3","title":"Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2017-11-28","conditions":"Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis","enrollment":149},{"nctId":"NCT02449031","phase":"","title":"Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-05-05","conditions":"Pseudomonas Aeruginosa in Cystic Fibrosis","enrollment":409},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":"Cystic Fibrosis, Infection, Pseudomonas","enrollment":16},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT01641822","phase":"PHASE3","title":"Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12","conditions":"Cystic Fibrosis","enrollment":107},{"nctId":"NCT01375049","phase":"PHASE2","title":"Aztreonam Lysine for Pseudomonas Infection Eradication Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-08","conditions":"Cystic Fibrosis","enrollment":105},{"nctId":"NCT01404234","phase":"PHASE3","title":"Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Cystic Fibrosis, Pseudomonas Aeruginosa","enrollment":61},{"nctId":"NCT00805025","phase":"PHASE2","title":"Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Bronchiectasis","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cayston®","genericName":"Cayston®","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs. Used for Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}